血清NSE、S100β、IL-6对脓毒症相关性脑病发生率及脓毒症患者预后的影响
|
摘要
目的探讨血清神经元特异烯醇化酶(NSE)、S100β蛋白(S100β)、白介素-6(IL-6)对脓毒症相关性脑病发生率及脓毒症患者预后的影响。方法回顾性分析我院130例脓毒症患者的临床资料,将发生脓毒症相关性脑病的患者设为发生组,将未发生脓毒症相关性脑病的患者设为未发生组。比较发生组与未发生组患者血清NSE、S100β、IL-6水平,并比较不同预后患者上述血清因子水平。结果脓毒症相关性脑病发生率为21.54%,预后不良发生率为11.54%。发生组患者血清NSE、S100β、IL-6水平均高于未发生组,预后不良患者血清NSE、S100β、IL-6水平均高于预后良好者(P<0.05)。结论脓毒症相关性脑病者血清NSE、S100β和IL-6水平均高于未发生者,预后不良患者血清NSE、S100β和IL-6水平均高于预后良好患者,建议动态监测3项指标变化以控制病情,改善预后。
Objective To investigate the influence of serum neuron specific enolase(NSE), S100β protein(S100β) and interleukin-6(IL-6) in the incidence of sepsis related encephalopathy and prognosis of patients with sepsis. Methods The clinical data of 130 patients with sepsis in our hospital were retrospectively analyzed. The patients with sepsis related encephalopathy were set as occurrence group, while those without sepsis related encephalopathy were set as non-occurrence group. The levels of serum NSE, S100β and IL-6 were compared between the occurrence group and the non-occurrence group, and the serum levels of above factors in patients with different prognosis were compared. Results The incidence of sepsis related encephalopathy was 21.54%, and the incidence of poor prognosis was 11.54%. The levels of serum NSE, S100β and IL-6 in the occurrence group were higher than those in the non-occurrence group, and those in patients with poor prognosis were higher than those in patients with good prognosis(P<0.05). Conclusion The levels of serum NSE, S100β and IL-6 in patients with sepsis related encephalopathy are higher than those in patients without sepsis related encephalopathy,and those in patients with poor prognosis are higher than those in patients with good prognosis. It is suggested to monitor the changes of three indicators dynamically to control the disease and improve the prognosis.
Objective To investigate the influence of serum neuron specific enolase(NSE), S100β protein(S100β) and interleukin-6(IL-6) in the incidence of sepsis related encephalopathy and prognosis of patients with sepsis. Methods The clinical data of 130 patients with sepsis in our hospital were retrospectively analyzed. The patients with sepsis related encephalopathy were set as occurrence group, while those without sepsis related encephalopathy were set as non-occurrence group. The levels of serum NSE, S100β and IL-6 were compared between the occurrence group and the non-occurrence group, and the serum levels of above factors in patients with different prognosis were compared. Results The incidence of sepsis related encephalopathy was 21.54%, and the incidence of poor prognosis was 11.54%. The levels of serum NSE, S100β and IL-6 in the occurrence group were higher than those in the non-occurrence group, and those in patients with poor prognosis were higher than those in patients with good prognosis(P<0.05). Conclusion The levels of serum NSE, S100β and IL-6 in patients with sepsis related encephalopathy are higher than those in patients without sepsis related encephalopathy,and those in patients with poor prognosis are higher than those in patients with good prognosis. It is suggested to monitor the changes of three indicators dynamically to control the disease and improve the prognosis.
引文
[1]李皖生,徐道剑,王国涛.参麦注射液治疗脓毒症临床效果及对LAC、NSE和S100B蛋白的影响[J].中华中医药学刊,2018,36(3):176-178.
[2]戴喜明,高青豹,胡清甫.醒脑静注射液联合床旁高流量持续血液净化治疗脓毒性休克48例临床分析[J].重庆医学,2016,45(14):1978-1980.
[3]陈灏珠,林果为,王吉耀.实用内科学[M].14版.北京:人民卫生出版社,2013:251-255.
[4]高戈,冯喆,常志刚,等.2012国际严重脓毒症及脓毒性休克诊疗指南[J].中华危重病急救医学,2013,25(8):501-505.
[5]中华医学会重症医学分会.中国严重脓毒症/脓毒性休克治疗指南(2014)[J].中华内科杂志,2015,54(6):401-426.
[6]王盛标,李涛,李云峰,等.4种评分系统对脓毒症患者预后的评估价值:附311例回顾性分析[J].中华危重病急救医学,2017,29(2):133-138.
[7]冯清,吴龙,艾宇航,等.神经元特异性烯醇化酶、中枢神经特异蛋白与白细胞介素-6在脓毒症相关性脑病中的诊断价值[J].中华内科杂志,2017,56(10):176-178.
[8]黄永光,吴冠祺,霍保善.支链氨基酸对脓毒性脑病患者血清神经元特异性烯醇化酶水平的影响[J].内科急危重症杂志,2017,23(3):204-206.
[9]李新,郑晓晶,崔巍,等.低分子肝素对脓毒症患者血浆TNF-α、IL-6及凝血功能的影响[J].疑难病杂志,2017,16(6):566-569.
[2]戴喜明,高青豹,胡清甫.醒脑静注射液联合床旁高流量持续血液净化治疗脓毒性休克48例临床分析[J].重庆医学,2016,45(14):1978-1980.
[3]陈灏珠,林果为,王吉耀.实用内科学[M].14版.北京:人民卫生出版社,2013:251-255.
[4]高戈,冯喆,常志刚,等.2012国际严重脓毒症及脓毒性休克诊疗指南[J].中华危重病急救医学,2013,25(8):501-505.
[5]中华医学会重症医学分会.中国严重脓毒症/脓毒性休克治疗指南(2014)[J].中华内科杂志,2015,54(6):401-426.
[6]王盛标,李涛,李云峰,等.4种评分系统对脓毒症患者预后的评估价值:附311例回顾性分析[J].中华危重病急救医学,2017,29(2):133-138.
[7]冯清,吴龙,艾宇航,等.神经元特异性烯醇化酶、中枢神经特异蛋白与白细胞介素-6在脓毒症相关性脑病中的诊断价值[J].中华内科杂志,2017,56(10):176-178.
[8]黄永光,吴冠祺,霍保善.支链氨基酸对脓毒性脑病患者血清神经元特异性烯醇化酶水平的影响[J].内科急危重症杂志,2017,23(3):204-206.
[9]李新,郑晓晶,崔巍,等.低分子肝素对脓毒症患者血浆TNF-α、IL-6及凝血功能的影响[J].疑难病杂志,2017,16(6):566-569.